Business

 


Emergency Contraception in the Netherlands

Netherlands emergency contraception market: EUR 5.4 million industry forecast by 2017


Companies & Markets

© companiesandmarkets.com
22.01.2014 15:49:01 - Emergency Contraception in the Netherlands - a new market research report on companiesandmarkets.com

(live-PR.com) - Brand NorLevo remained the sole product in the Netherlands emergency contraception market. There was no advertising for the brand and consumers are able to find further information at a special website, www.norlevo.nl.

OTC emergency contraception began when these products were switched from prescription only to OTC in late 2004. Despite initially more optimistic prospects, sales have remained relatively low in the

 

Netherlands, perhaps explained by the relatively low level of unwanted pregnancies amongst the young population.

Emergency contraception is expected to witness positive but stable growth over the forecast period, rising to €5.4 million in 2017, up by 28% in constant value.

Click for report details: www.companiesandmarkets.com/Market/Consumer-Good ..

Browse all Consumer Goods Market Research Reports www.companiesandmarkets.com/Market/Consumer-Good ..

Browse all Consumer Goods Company Profile Reports www.companiesandmarkets.com/Market/Consumer-Good ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Re ..

About Us
Companiesandmarkets.com aims to provide clients with the widest array of reports and market research across all of our 27 industry sectors. Companiesandmarkets.com’s team of analysts are available to offer clients specific advice on finding relevant information and also purchasing the correct market research reports for their specific business needs. Over 100,000 companies are listed in Companiesandmarkets.com´s online reports database, providing clients with an extensive coverage not only of company profiles but also of high value and insightful market reports.


Author:
Mike King
e-mail
Phone: 44 0203 086 8600


 

Disclaimer: If you have any questions regarding information in this article please contact the author. Please do not contact Live-PR.com. We are not able to assist you. Live-PR.com disclaims content contained in this article. Live-PR.com is not authorized to give any information about content and not responsible for content posted by third party.
refer this article
Print This Article